Advertisement
JAZZ vs ZYME
Which Stock Would AI Choose? Jazz Pharmaceuticals (JAZZ) vs. Zymeworks (ZYME) Stock Comparison
Key Takeaways
- Jazz Pharmaceuticals (JAZZ) has delivered robust year-to-date gains of approximately 49%, supported by strong revenue growth and commercial execution across its portfolio.
- Zymeworks (ZYME) trades at a significantly lower market capitalization and exhibits higher volatility, with recent analyst attention focused on pipeline advancements and strategic transactions.
- The two companies maintain a longstanding collaboration on zanidatamab (Ziihera), a HER2-targeted bispecific antibody, creating interconnected exposure to oncology developments.
- JAZZ demonstrates greater scale and diversified revenue streams compared to ZYME's more concentrated focus on antibody engineering and partnered assets.
- Recent market activity shows JAZZ benefiting from consistent momentum, while ZYME has seen price targets adjusted amid positive clinical data readouts and M&A activity.
- Relative performance highlights trade-offs between established pharmaceutical stability and emerging biotechnology optionality in the current environment.
Introduction
This comparison examines JAZZ and ZYME to provide traders and investors with an objective view of their relative positioning. Jazz Pharmaceuticals operates as a commercial-stage biopharmaceutical company with multiple approved products, while Zymeworks focuses on developing multifunctional biotherapeutics. The analysis is relevant for market participants seeking to understand performance contrasts within the healthcare sector, particularly those evaluating established revenue generators against development-stage innovators with partnered assets. Data draws from recent market activity and verifiable corporate developments.
Jazz Pharmaceuticals (JAZZ) Overview and Recent Performance
Jazz Pharmaceuticals develops and commercializes medicines primarily in neuroscience and oncology. In recent weeks, the stock has shown resilience amid broader market conditions, with year-to-date returns near 49% and one-year gains exceeding 120%. Recent quarterly results reflected 19% year-over-year revenue growth to $1.1 billion, driven by commercial execution across key franchises. Sentiment has been supported by operational discipline and pipeline progress, contributing to relative outperformance versus major indices over multi-month periods. The company's larger scale provides a buffer against single-asset volatility.
Zymeworks (ZYME) Overview and Recent Performance
Zymeworks is a biotechnology company specializing in antibody-based therapeutics using its proprietary platforms. In recent market activity, shares have traded around the low $20s, reflecting a market capitalization well below that of larger peers. The stock posted positive year-to-date returns but with greater price fluctuations than broader benchmarks. Recent developments include positive clinical data for zanidatamab in gastroesophageal adenocarcinoma and announcements of strategic transactions, such as acquisitions. Analyst coverage has featured upward price target revisions, reflecting attention on pipeline catalysts and royalty streams from partnerships.
Trending AI Robots
Tickeron maintains a curated section highlighting its top-performing AI trading bots through the Trending AI Robots page. The platform offers hundreds of AI trading bots that trade thousands of different tickers across varied market conditions. Only those demonstrating the strongest alignment with prevailing trends, consistent risk-adjusted returns, and suitable strategies earn placement in this section. Available bots span a wide range of performance metrics, with many showing annualized returns in the 20-100%+ range depending on timeframe and market regime, alongside varying win rates, drawdowns, and trading frequencies. Each bot employs distinct styles, strategies, and ticker sets, allowing users to match approaches to their objectives. Explore the full selection at the Trending AI Robots page for detailed statistics.
Head-to-Head Comparison
Business model: JAZZ operates with diversified commercial products generating recurring revenue, whereas ZYME relies more heavily on development milestones, royalties, and partnered programs. Growth drivers: Jazz benefits from established sales infrastructure and multiple franchises, while Zymeworks centers on clinical advancement of its HER2 bispecific and platform expansion. Recent momentum: JAZZ has exhibited steadier upward price trajectory in recent weeks compared to ZYME's more variable movement. Risk factors: The smaller ZYME carries higher clinical and dilution risk, offset by potential upside from data readouts and acquisitions. Sector exposure: Both operate in oncology and biopharma, with shared exposure via their zanidatamab collaboration. Market sentiment: JAZZ reflects broader acceptance of proven execution, while ZYME attracts interest from catalyst-driven investors.
Tickeron AI Verdict
Based on observable factors such as trend consistency, revenue stability, and relative market positioning in recent activity, Tickeron’s AI models would currently assign a higher probabilistic preference to JAZZ for its demonstrated momentum and scale. ZYME presents compelling optionality tied to clinical and transactional catalysts but with elevated variability. This assessment reflects pattern recognition across performance metrics rather than forward projections.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAZZ is a Hold and ZYME is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JAZZ’s FA Score shows that 0 FA rating(s) are green whileZYME’s FA Score has 0 green FA rating(s).
- JAZZ’s FA Score: 0 green, 5 red.
- ZYME’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JAZZ’s TA Score shows that 4 TA indicator(s) are bullish while ZYME’s TA Score has 5 bullish TA indicator(s).
- JAZZ’s TA Score: 4 bullish, 3 bearish.
- ZYME’s TA Score: 5 bullish, 6 bearish.
Price Growth
JAZZ (@Biotechnology) experienced а +3.80% price change this week, while ZYME (@Biotechnology) price change was +14.13% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +15.94%, and the average quarterly price growth was +3349.70%.
Reported Earning Dates
JAZZ is expected to report earnings on Nov 11, 2026.
ZYME is expected to report earnings on Nov 10, 2026.
Industries' Descriptions
@Biotechnology (+3.69% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| JAZZ | ZYME | JAZZ / ZYME | |
| Capitalization | 16.5B | 2.05B | 805% |
| EBITDA | 675M | -104.03M | -649% |
| Gain YTD | 49.576 | 8.887 | 558% |
| P/E Ratio | 17.39 | N/A | - |
| Revenue | 4.44B | 81.3M | 5,460% |
| Total Cash | 2.87B | 365M | 787% |
| Total Debt | 5.42B | 17M | 31,865% |
JAZZ | ZYME | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 77 Overvalued | 72 Overvalued | |
PROFIT vs RISK RATING 1..100 | 47 | 100 | |
SMR RATING 1..100 | 88 | 98 | |
PRICE GROWTH RATING 1..100 | 39 | 38 | |
P/E GROWTH RATING 1..100 | 100 | 59 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ZYME's Valuation (72) in the Pharmaceuticals Major industry is in the same range as JAZZ (77) in the Pharmaceuticals Other industry. This means that ZYME’s stock grew similarly to JAZZ’s over the last 12 months.
JAZZ's Profit vs Risk Rating (47) in the Pharmaceuticals Other industry is somewhat better than the same rating for ZYME (100) in the Pharmaceuticals Major industry. This means that JAZZ’s stock grew somewhat faster than ZYME’s over the last 12 months.
JAZZ's SMR Rating (88) in the Pharmaceuticals Other industry is in the same range as ZYME (98) in the Pharmaceuticals Major industry. This means that JAZZ’s stock grew similarly to ZYME’s over the last 12 months.
ZYME's Price Growth Rating (38) in the Pharmaceuticals Major industry is in the same range as JAZZ (39) in the Pharmaceuticals Other industry. This means that ZYME’s stock grew similarly to JAZZ’s over the last 12 months.
ZYME's P/E Growth Rating (59) in the Pharmaceuticals Major industry is somewhat better than the same rating for JAZZ (100) in the Pharmaceuticals Other industry. This means that ZYME’s stock grew somewhat faster than JAZZ’s over the last 12 months.
| JAZZ | ZYME | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 82% |
| Stochastic ODDS (%) | 3 days ago 66% | 3 days ago 83% |
| Momentum ODDS (%) | 3 days ago 59% | 3 days ago 77% |
| MACD ODDS (%) | 3 days ago 55% | 3 days ago 76% |
| TrendWeek ODDS (%) | 3 days ago 63% | 3 days ago 83% |
| TrendMonth ODDS (%) | 3 days ago 67% | 3 days ago 84% |
| Advances ODDS (%) | 6 days ago 61% | 6 days ago 84% |
| Declines ODDS (%) | 4 days ago 54% | 21 days ago 81% |
| BollingerBands ODDS (%) | 3 days ago 71% | 3 days ago 80% |
| Aroon ODDS (%) | 3 days ago 61% | 3 days ago 90% |
Advertisement
ZYME and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with JAZZ. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then JAZZ could also see price increases.
| Ticker / NAME | Correlation To ZYME | 1D Price Change % | ||
|---|---|---|---|---|
| ZYME | 100% | +7.90% | ||
| JAZZ - ZYME | 52% Loosely correlated | +2.24% | ||
| REPL - ZYME | 46% Loosely correlated | +5.12% | ||
| MLTX - ZYME | 40% Loosely correlated | -0.69% | ||
| BBIO - ZYME | 39% Loosely correlated | -1.74% | ||
| VERA - ZYME | 38% Loosely correlated | +3.25% | ||
More | ||||